Terumo Blood and Cell Technologies (Terumo BCT) and FUJIFILM Irvine Scientific will collaborate to accelerate T cell expansion for cell therapy developers. The partnership focuses on using Fujifilm’s PRIME-XV T Cell Expansion Media in conjunction with Terumo BCT’s Quantum Flex Cell Expansion System.
This collaboration aims to simplify and scale T cell expansion processes, reducing barriers for developers, particularly early-stage companies. These developers often encounter significant challenges in scaling manufacturing processes and typically require substantial investments for developing their own methods.
Lakewood-based Terumo BCT’s protocols, tested with Fujifilm’s GMP-compliant media, are designed to lessen the challenges associated with T cell expansion, including time and cost. “We’re optimistic about the impact this collaboration will have on the industry by advancing process standardization and reducing risks in therapy development through integrated proven solutions,” said Veerle d’Haenens, general manager of Global Therapy Innovations at Terumo BCT.
The collaboration provides a reliable option for expanding T cells at scale, utilizing GMP manufactured media to meet regulatory requirements. Fujifilm’s PRIME-XV T Cell Expansion Media includes a Drug Master File (DMF) to help expedite approval for therapeutic treatments.
The partnership also represents a focused effort to enable faster and more efficient development of cell therapies for patients.
